Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database

Basit Öğe Kaydı
dc.authoridSaadettin Kılıçkap / 0000-0003-1637-7390en_US
dc.authorscopusidSaadettin Kılıçkap / 8665552100
dc.authorwosidSaadettin Kılıçkap / DXP-4273-2022
dc.contributor.authorYekedüz, Emre
dc.contributor.authorErtürk, İsmail
dc.contributor.authorTural, Deniz
dc.contributor.authorKaradurmuş, Nuri
dc.contributor.authorKarakaya, Serdar
dc.contributor.authorKılıçkap, Saadettin
dc.date.accessioned2021-11-11T11:55:03Z
dc.date.available2021-11-11T11:55:03Z
dc.date.issued2021en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractAim: The authors present real-world data on the efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC). Methods: The Turkish Oncology Group Kidney Cancer Consortium (TKCC) database includes patients with mRCC from 13 cancer centers in Turkey. Patients with mRCC treated with nivolumab in the second line and beyond were extracted from the TKCC database. Results: A total of 173 patients were included. The rates of patients treated with nivolumab in the second, third, fourth and fifth lines were 47.4%, 32.4%, 14.5% and 5.7%, respectively. The median overall survival and progression-free survival were 24.2 months and 9.6 months, respectively. Nivolumab was discontinued owing to adverse events in 11 (6.4%) patients. Conclusion: Nivolumab was effective in patients with mRCC and no new safety signal was observed.en_US
dc.description.versionWOS:000713725100001en_US
dc.identifier.citationYekedüz, E., Ertürk, İ., Tural, D., Karadurmuş, N., Karakaya, S., Hızal, M., Arıkan, R., Arslan, Ç., Taban, H., Küçükarda, A., Öztaş, N. Ş., Sever, Ö. N., Uçar, G., Can, O., Nahit Şendur, M. A., Demirci, U., Kılıçkap, S., Çiçin, İ., Öksüzoğlu, B., Özgüroğlu, M., … Ürün, Y. (2021). Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database. Future oncology (London, England), 10.2217/fon-2021-0717. Advance online publication.en_US
dc.identifier.doi10.2217/fon-2021-0717en_US
dc.identifier.pmid34726480en_US
dc.identifier.scopus2-s2.0-85120620215en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.urihttps://doi.org/10.2217/fon-2021-0717
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2227
dc.identifier.wosWOS:000713725100001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKılıçkap, Saadettin
dc.language.isoenen_US
dc.publisherFuture Medicineen_US
dc.relation.ispartofFuture Oncol .en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectImmunotherapyen_US
dc.subjectKidney Canceren_US
dc.subjectNivolumaben_US
dc.subjectRenal Cell Carcinomaen_US
dc.titleNivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium databaseen_US
dc.typeArticleen_US

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu